Evidence map›Paper›PMID 33413501›Full record

ArticleJournal of experimental & clinical cancer research : CR2021

Alcoholic fatty liver disease inhibited the co-expression of Fmo5 and PPARα to activate the NF-κB signaling pathway, thereby reducing liver injury via inducing gut microbiota disturbance.

Lingjian Kong, Jing Chen, Xiaoli Ji, Qian Qin, Huiyu Yang, Dan Liu, Deliang Li, Meiling Sun

Open access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
6.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 74 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Frontiers in microbiology · 2025
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Lingjian KongDepartment of Gastroenterology, The First Affiliated Hospital of Zhengzhou University, No.1 Jianshe East Road, Henan Province, Zhengzhou, 450052, PR China. konggewww@163.com.
Jing ChenDepartment of Gastroenterology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, 150086, PR China.
Xiaoli JiDepartment of Intervention, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, 450052, PR China.
Qian QinPhysical Examination Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, 450052, PR China.
Huiyu YangDepartment of Gastroenterology, The First Affiliated Hospital of Zhengzhou University, No.1 Jianshe East Road, Henan Province, Zhengzhou, 450052, PR China.
Dan LiuDepartment of Gastroenterology, The First Affiliated Hospital of Zhengzhou University, No.1 Jianshe East Road, Henan Province, Zhengzhou, 450052, PR China.
Deliang LiDepartment of Gastroenterology, The First Affiliated Hospital of Zhengzhou University, No.1 Jianshe East Road, Henan Province, Zhengzhou, 450052, PR China.
Meiling SunDepartment of Gastroenterology, ZhuJiang Hospital of Southern Medical University, Guangzhou, Guangdong Province, 510280, PR China.
First Affiliated Hospital of Zhengzhou University · CNSecond Affiliated Hospital of Harbin Medical University · CNZhujiang Hospital · CN

Funding

Basic research project of Henan Academy of Medical and Pharmaceutical YYYJK201814
6 · The paper itself

Abstract

backgroundAlcohol-induced intestinal dysbiosis disrupts and inflammatory responses are essential in the development of alcoholic fatty liver disease (AFLD). Here, we investigated the effects of Fmo5 on changes in enteric microbiome composition in a model of AFLD and dissected the pathogenic role of Fmo5 in AFLD-induced liver pathology.

methodsThe expression profile data of GSE8006 and GSE40334 datasets were downloaded from the GEO database. The WGCNA approach allowed us to investigate the AFLD-correlated module. DEGs were used to perform KEGG pathway enrichment analyses. Four PPI networks were constructed using the STRING database and visualized using Cytoscape software. The Cytohubba plug-in was used to identify the hub genes. Western blot and immunohistochemistry assays were used to detect protein expression. ELISA assay was used to detect the levels of serum inflammatory cytokines. Lipid droplets in the cytoplasm were observed using Oil Red O staining. Apoptosis was detected using a TUNEL assay and flow cytometry analysis. ROS levels were detected using flow cytometry analysis. Nuclear translocation of NF-κB p65 was observed using immunofluorescence staining. Co-immunoprecipitation was used to detect the co-expression of PPARα and Fmo5 in L02 cells. 16S rDNA sequencing defined the bacterial communities in mice with AFLD.

resultsFmo5 is a key DEG and is closely associated with the gut microbiota and PPAR signaling pathway. Gut microbiome function in AFLD was significantly related to the PPAR signaling pathway. AFLD induced shifts in various bacterial phyla in the cecum, including a reduction in Bacteroidetes and increased Firmicutes. Fmo5 and PPARα co-expression in cell and animal models with AFLD, which decreased significantly. Silencing of Fmo5 and PPARα aggravated the functions of AFLD inducing apoptosis and inflammatory response, promoting liver injury, and activating the NF-κB signaling pathway in vivo and in vitro. The NF-κB inhibitor abolished the functions of silencing of Fmo5 and PPARα promoting AFLD-induced apoptosis, inflammatory response, and liver injury.

conclusionOur data indicated that the co-expression of Fmo5 and PPARα was involved in AFLD-related gut microbiota composition and alleviated AFLD-induced liver injury, apoptosis, and inflammatory response by inhibiting the nuclear translocation of NF-κB p65 to inhibit the NF-κB signaling pathway.

Indexed as

AnimalsDisease Models, AnimalFatty Liver, AlcoholicGastrointestinal MicrobiomeHumansMaleMiceNF-kappa BOxygenasesPPAR alphaSignal TransductionTransfectiondimethylaniline monooxygenase (N-oxide forming)NF-kappa BOxygenasesPPAR alphaAlcoholic fatty liver diseaseFmo5Gut microbiota disturbanceLiver injuryNF-κBPPARα

Identifiers

PMID33413501
PMCPMC7788704
OpenAlexW3113282045

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.